Does Ledipasvir-Sofosbuvir Teatment Prevent Hepatocellular Cancer in Hepatitis C Patients? Single Center Real Life Data

Backgraund/Aims: We aimed to evaluate treated with ledipasvir-sofosbuvir ± ribavirin in noncirrhotic and cirrhotic patients due to hepatitis C and to detect hepatocellular cancer (HCC) frequency in these patients. Materials and Methods: The characteristics and treatment outcomes of the patients were evaluated. Patients treated with ledipasvir-sofosbuvir ± ribavirin 3 or 6 months. The patients were followed by monthly outpatient controls, during theraphy, than once in 3 months. Results : Of the total 35 patients, 18 (52%) were male and mean age was 63.2 ± 11.9 (range 22-86) years. 22 of the patients (63%) were cirrhotic. 27 (77%) patients were over 60 years old. 34 patients (97%) were genotype 1-1a-1b, and 1 genotype 4. In two patient, HCC was detected, second month of treatment and 2 months after the end of treatment. Conclusion: Our HCV patients are mostly genotype I, cirrhotic, two of third elderly, two of third treatment experienced. Three patients died due to HCC, hepatic failure and CRF, and two patients had HCC during and after treatment. Ledipasvir-sofosuvir ± ribavirin therapy of chronic hepatitis C does not alter the short-term risk for HCC in patients with liver cirrhosis.

Keywords: HCV, ledispasvir-sofosbuvir, ribavirin, HCC